CA2574987A1 - Compositions d'acide nicotinique permettant de traiter l'hyperlipidemie et procedes connexes - Google Patents
Compositions d'acide nicotinique permettant de traiter l'hyperlipidemie et procedes connexes Download PDFInfo
- Publication number
- CA2574987A1 CA2574987A1 CA002574987A CA2574987A CA2574987A1 CA 2574987 A1 CA2574987 A1 CA 2574987A1 CA 002574987 A CA002574987 A CA 002574987A CA 2574987 A CA2574987 A CA 2574987A CA 2574987 A1 CA2574987 A1 CA 2574987A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- nicotinic acid
- sustained release
- patient
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 190
- 235000001968 nicotinic acid Nutrition 0.000 title claims abstract description 134
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 134
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 229960003512 nicotinic acid Drugs 0.000 title claims abstract description 85
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title description 27
- 238000009472 formulation Methods 0.000 claims abstract description 50
- 239000012730 sustained-release form Substances 0.000 claims abstract description 43
- 238000013268 sustained release Methods 0.000 claims abstract description 41
- 238000005469 granulation Methods 0.000 claims abstract description 28
- 230000003179 granulation Effects 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 230000008961 swelling Effects 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims abstract description 11
- 239000011159 matrix material Substances 0.000 claims abstract description 11
- 206010067125 Liver injury Diseases 0.000 claims abstract description 10
- 239000011230 binding agent Substances 0.000 claims abstract description 10
- 231100000234 hepatic damage Toxicity 0.000 claims abstract description 10
- 230000008818 liver damage Effects 0.000 claims abstract description 10
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 230000001965 increasing effect Effects 0.000 claims abstract description 8
- 239000007909 solid dosage form Substances 0.000 claims abstract description 8
- 238000009736 wetting Methods 0.000 claims abstract description 6
- 210000004185 liver Anatomy 0.000 claims abstract description 5
- 230000036571 hydration Effects 0.000 claims abstract description 4
- 238000006703 hydration reaction Methods 0.000 claims abstract description 4
- 239000000314 lubricant Substances 0.000 claims abstract description 4
- 239000012466 permeate Substances 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 26
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 238000008214 LDL Cholesterol Methods 0.000 claims description 10
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 10
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 10
- 150000003626 triacylglycerols Chemical class 0.000 claims description 10
- 229940116269 uric acid Drugs 0.000 claims description 10
- 238000007449 liver function test Methods 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims description 6
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 5
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 4
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000007686 hepatotoxicity Effects 0.000 claims description 2
- 239000007939 sustained release tablet Substances 0.000 claims 1
- 229940033757 niaspan Drugs 0.000 description 49
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 14
- 102000015779 HDL Lipoproteins Human genes 0.000 description 12
- 108010010234 HDL Lipoproteins Proteins 0.000 description 12
- 229920003091 Methocel™ Polymers 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 10
- 235000021355 Stearic acid Nutrition 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 9
- 239000008117 stearic acid Substances 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229940069328 povidone Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229920003082 Povidone K 90 Polymers 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 125000000627 niacin group Chemical group 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000004605 External Lubricant Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007056 liver toxicity Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- NSFYKDVWNTWJOK-UHFFFAOYSA-K aluminum;pyridine-3-carboxylate Chemical compound [Al+3].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 NSFYKDVWNTWJOK-UHFFFAOYSA-K 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- NPUACKRELIJTFM-UHFFFAOYSA-N cr gas Chemical compound C1=NC2=CC=CC=C2OC2=CC=CC=C21 NPUACKRELIJTFM-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960000827 niceritrol Drugs 0.000 description 1
- 229960000839 nicotinyl alcohol tartrate Drugs 0.000 description 1
- NPORIZAYKBQYLF-LREBCSMRSA-N nicotinyl alcohol tartrate Chemical compound OCC1=CC=CN=C1.OC(=O)[C@H](O)[C@@H](O)C(O)=O NPORIZAYKBQYLF-LREBCSMRSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US814,974 | 1997-03-06 | ||
| US08/814,974 US6129930A (en) | 1993-09-20 | 1997-03-06 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| CA002283159A CA2283159C (fr) | 1997-03-06 | 1998-03-06 | Compositions d'acide nicotinique permettant de traiter l'hyperlipidemie et procedes connexes |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002283159A Division CA2283159C (fr) | 1997-03-06 | 1998-03-06 | Compositions d'acide nicotinique permettant de traiter l'hyperlipidemie et procedes connexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2574987A1 true CA2574987A1 (fr) | 1998-09-11 |
Family
ID=37890085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002574987A Abandoned CA2574987A1 (fr) | 1997-03-06 | 1998-03-06 | Compositions d'acide nicotinique permettant de traiter l'hyperlipidemie et procedes connexes |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2574987A1 (fr) |
-
1998
- 1998-03-06 CA CA002574987A patent/CA2574987A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2283159C (fr) | Compositions d'acide nicotinique permettant de traiter l'hyperlipidemie et procedes connexes | |
| US20070225342A1 (en) | Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor | |
| US20080300284A1 (en) | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | |
| US6818229B1 (en) | Intermediate release nicotinic acid compositions for treating hyperlipidemia | |
| US6406715B1 (en) | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles | |
| US6746691B2 (en) | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics | |
| US20130005779A1 (en) | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics | |
| US20030157153A1 (en) | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics | |
| US20110301207A1 (en) | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia | |
| AU775967B2 (en) | Starter kit containing nicotinic acid compositions | |
| CA2574987A1 (fr) | Compositions d'acide nicotinique permettant de traiter l'hyperlipidemie et procedes connexes | |
| AU2009200874A1 (en) | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |